Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels

Erlotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for the treatment of non-small cell lung cancer and when combined with gemcitabine for pancreatic cancer. Dose reduction of erlotinib in patients with severe hepatic impairment has been established. We pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Czejka, M., Sahmanovic, A., Buchner, P., Steininger, T., Dittrich, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2013
Materias:
Published online: December, 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901587/
https://www.ncbi.nlm.nih.gov/pubmed/24474924
http://dx.doi.org/10.1159/000357211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901587/
https://www.ncbi.nlm.nih.gov/pubmed/24474924
http://dx.doi.org/10.1159/000357211

Ejemplares similares